Back to mobile site

Meridian Bioscience (VIVO) Misses Q3 EPS by 1c

August 5, 2022 8:03 AM EDT

Meridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.16, $0.01 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $67.8 million versus the consensus estimate of $66.8 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings